Background: In multiple sclerosis (MS) regional grey matter (GM) atrophy has been associated with disability progression. Objective: The aim of this study was to compare regional GM volume changes in relapsing-remitting MS (RRMS) patients with progressive and stable disability, using voxel-based morphometry (VBM). Methods: We acquired baseline and 1-year follow-up 3-dimensional (3D) T1-weighted magnetic resonance imaging (MRI) data of RRMS patients, using two 1.5-Tesla scanners. Patients were matched pair-wise with respect to age, gender, disease duration, medication, scanner and baseline Expanded Disability Status Scale (EDSS) into 13 pairs, with either progressive EDSS (≥ 1 point change y -1 ) or stable EDSS, as well as into 29 pairs with either progressive Multiple Sclerosis Functional Composite (MSFC) at ≥ 0.25% decrease in y -1 in any component, or stable MSFC. We analysed longitudinal regional differences in GM volumes in the progressive and stable EDSS and MSFC groups, respectively, using VBM. Results: Significant GM volume reductions occurred in the right precuneus, in the progressive EDSS group. Differential between-group effects occurred in the right precuneus and in the postcentral gyrus. Further longitudinal GM volume reductions occurred in the right orbicular gyrus, in the progressive MSFC group, but no between-group differences were observed (non-stationary cluster-wise inference, all P corrected < 0.05). Conclusion: These results suggested a direct association of disability progression and regional GM atrophy in RRMS.
Introduction
Historically classified as a white matter (WM) disease, multiple sclerosis (MS) has been associated with both grey matter (GM) lesions and GM atrophy in magnetic resonance imaging (MRI). [1] [2] [3] GM atrophy develops faster than WM atrophy and predominates in early disease phases. 4 Previous studies have shown that global, as well as regional, GM volume loss in the fronto-temporo-parietal regions correlate with disability in relapsing-remitting MS (RRMS) patients. 2, 3, 5 Previous longitudinal voxel-based morphometry (VBM) studies indicate progressive regional GM atrophy in RRMS; 6, 7 however, there are few studies Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis combining GM atrophy and disability progression ( Table  1) . [8] [9] [10] [11] [12] To the best of our knowledge, only two longitudinal studies directly address the relationship of regional GM atrophy and disability progression in MS patients. 10, 13 Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC) are amongst the most widely used and clinically-relevant disability outcome measures. 14 EDSS includes a wide range of neurological functions and enables the comparison of features on a scale of 0 -10 for individual and groups of patients, over time. MSFC is a standardised, quantitative assessment instrument with three domains, i.e. ambulation, upperextremity function and cognition, that enables direct comparison within a study, and correlates with EDSS. 14 In the present study, we investigated regional GM volume (GMV) changes in RRMS patients with stable disability, compared to patients with progressive disability using VBM, a non-biased measure of regional differences of GMVs in the whole brain. 15, 16 We compared regional GM volume changes over 1 year, in groups of (a) RRMS patients with progressive EDSS versus stable EDSS and (b) patients with progressive MSFC versus stable MSFC.
Based on previous data, 10, 13 we hypothesised that the development of GMV reductions is related to progressive disability in RRMS. We expected to find a closer relationship between regional GMV reductions and disability in RRMS patients who progressed over the interscan interval, as compared to patients with stable disability. In particular, we expected to see changes in specific fronto-temporoparietal cortical areas, 3, 5, 10, 17 reflecting clinical dysfunction in specific functional domains, captured by EDSS and MSFC, respectively.
Materials and methods Patients
We selected matched pairs of subjects from a total of 239 Caucasian patients (74 men, 165 women) with a diagnosis of clinically definite RRMS. 18 The subjects came from the case-control study for genotype-phenotype associations in MS ('GeneMSA'; GlaxoSmithKline, UK), recruited in two clinical centres that were participating in the GeneMSA consortium, and followed for 3 years. We set strict exclusion criteria (Figure 1 ). There was overlap between subjects in this study and in those used in previous magnetic resonance structural imaging studies. 6, 19 The study was approved by the local ethical standards committee and we obtained written informed consent from each subject.
Based on previous studies, 10, 11, 14 disability progression was defined as an increase of ≥ 1.0 point in EDSS or of ≥ 0.25% for any of the three components in MSFC over 1 year. Patients who were defined as clinically stable showed no change in EDSS or no change ≥ 0.25%, for any of the three components in MSFC, over 1 year. 10, 11 The MSFC is a 3-part, quantitative assessment instrument that measures arm, leg and cognitive function with the 9-Hole Peg Test (HPT), the Timed 25-Foot Walk, and the Paced Auditory Serial Addition Test 3-second version (PASAT3), respectively. Patients with fluctuations (i.e. ≥ +/-1 point) in EDSS in the year before/after scan were excluded. In total, 35 patients showed EDSS progression and 75 had stable EDSS.
To avoid the confounding effects of sex, medication and age, patients with progressive and stable disability were pair-wise matched, accordingly. Then each subject with progressive disability was assigned a patient having stable disability that did not differ by more than ± 10 years in age at baseline. They were assigned to a subject who differed by less than ± 5 years in disease duration and less than ± 0.5 difference in EDSS at baseline, to rule out potential bias by differences in EDSS or disease duration, and subsequently GM atrophy at baseline. Thus, we obtained 19 pairs of RRMS patients with either stable or progressive EDSS.
Only the MSFC data of centre one were available (36 patients with progressive MSFC; 87 with stable MSFC). Patients were matched according to sex, medication, age (± 10 years) and disease duration (± 5 years), to establish 29 pairs of RRMS patients stable and progressive in MSFC, respectively. In a subgroup analysis, we assessed the relationship between cognition and regional GM volume at baseline by means of the PASAT3. 20 
MR image acquisition
All subjects were scanned three times (baseline, year 1 follow-up and year 2 follow-up) using one of two 1.5T MR systems (centre one: Siemens Avanto; centre two: Siemens Vision) with similar protocols. For VBM analysis, 3D-T1 images were acquired (magnetisation-prepared rapid gradient echo (MP-RAGE); TR: 7 -20.8 ms; TE: 2 -4 ms; TI: 300 -400 ms), consisting of isotropic 1 x 1 x 1 mm 3 voxels. Additionally, we obtained dual echo-T2-weighted images (TR: 2000 -4000 ms; TE: 14 -20/80 -108 ms; interleaved axial 3.0 mm-thick slices with an in-plane resolution of 1.0 x 1.0 mm 2 ) and post-contrast T1-weighted spin-echo images (TR: 467 -650 ms, TE: 8 -17 ms; axial 3.0 mmthick slices with an in-plane resolution of 1.0 x 1.0 mm 2 ).
MR imaging data analysis
MR imaging data analysis has already been extensively described before. 19 Briefly, MR images were analysed using Statistical Parametric Mapping software (SPM5, version 958) running under the MATLAB 7.0 (R14) environment.The images were processed using the VBM toolbox v1.03 (http://dbm.neuro.uni-jena.de/vbm/), as previously described. 6 The method was modified to reduce the influence of MS lesions in the process, which could alter the normalisation and segmentation procedures. To prevent WM lesions from being misclassified as GM, lesions identified on T2 images were masked from the 3-dimensional (3D) MP-RAGE images 19 and outlined on the proton density scans (to calculate 3D binary masks and quantify the area of previously identified brain lesions). 21 The 3D binary masks were then co-registered to the MP-RAGE to remove the MS lesions.
In the segmentation step, images were spatially normalised into the same stereotactic space. In SPM5, prior probability maps that are relevant to tissue segmentation are warped to the individual brains, making the creation of a customised template unnecessary. The normalisation was performed by first estimating the optimum 12-variable affine transformation for matching images and then optimising the normalisation, using 16 non-linear iterations, using 6 x 8 x 6 basis functions to account for global non-linear shape differences, as was described before. 19 To preserve the total within-voxel volume, every voxel's signal intensity in the segmented GM images was multiplied by the Jacobian determinants derived from the spatial normalisation. We used the analysis of these modulated datasets to detect regional differences in absolute tissue volume. The potential bias coming from errors in registration, in segmentation and in warping were minimised by visually checking, as described elsewhere. 19 Finally, in order to increase the signal-to-noise ratio and to account for variation in normal gyral anatomy, all images were smoothed using a 5 mm full-width-at-half-maximum isotropic Gaussian kernel. 6, 19 
Statistical analysis of demographic data
The median and interquartile range, or the mean and SD were used to describe clinical and MRI characteristics. To compare demographic and clinical variables, we used chisquared test, paired t-test, Mann-Whitney-U and Wilcoxon tests. We performed all statistics using SPSS 15.0 (SPSS Inc.), considering a significance level of p < 0.05.
Statistical analysis of MRI data
To investigate longitudinal regional differences in GMV between the groups, normalised modulated GM volumes were analysed at voxel level by fitting an analysis of covariance (ANCOVA) model. We chose a full-factorial design, with the centred covariates scanner and global GMV at baseline, in order to assess additional nuisance variation due to head size differences. GMV at baseline was calculated by SPM5.
Baseline brain atrophy has been correlated to EDSS after follow-up, several years later. 11 Additionally, all analyses were repeated, including T2 and T1 lesion volumes (LVs) as additional covariates. Before entering the linear regression models, T2 and T1 LV were transformed, to reduce skew of LVs and reduce the impact of outlier lesion volumes, using logarithms (e.g. logT2LV and logT1LV).
In a previous study, we found that the effect of the scanner was negligible, compared to disease-related effects in RRMS patients of the same dataset, thus allowing to pool data from two different 1.5 T scanners. However, to address this point, here we performed additional analyses of 13 patients per group, each pair-wise matched for scanner effect of scanner.
We performed F-tests to investigate if there were any longitudinal GM changes in the progressive and stable group, followed by subsequent t-tests contrasting the progressive group against the stable group.
Statistical maps were assessed for significance, with cluster size interference adjusted for non-stationary. We used a cluster-defining threshold of P = 0.001 uncorrected. We considered the clusters significant at the family-wise error (FWE), corrected P FWE < 0.05 cluster level, corrected for a whole-brain search. Localisation of significant clusters is described elsewhere. 19 Spearman rank correlation was used for correlations between regional GM atrophy and PASAT3 at baseline. The regression was run with centred covariates of age, gender and disease duration.
Results

Clinical and MRI (non-VBM) characteristics
We report the clinical and MRI characteristics of the different patient groups in Table 2 and Table 3 . The groups did not significantly differ regarding their clinical and MRI characteristics, except for disability measures in MSFC and EDSS, for relapses in the EDSS groups, and for T2LV in the MSFC groups.
Longitudinal changes in GMV.
EDSS. Over 1 year, we found there was a significant reduction of cortical GMV (cluster P FWE < 0.05) in the right precuneus (Figure 2(a) ; Table 4 (a)) in the progressive group. In contrast, no GMV changes were found in the group of patients with stable EDSS over time (minimum P FWE = 0.283). We found a statistically significant differential effect of GMV development between both groups, in the right precuneus (Figure 3 (a), Table 4 (b)).
The results of the centre-matched patients basically confirmed those of the first analysis, showing regional GMV reduction in the right precuneus in patients with progressive EDSS, but no change in the stable group (Figure 2(b) , Table 4 (c)). We found statistically significant differential effects between RRMS patients with progressive and with stable EDSS in the right precuneus, and additionally in the right postcentral gyrus (Figure 3 Multiple Sclerosis Functional Composite. In the group with progressive MSFC, cortical GMV decreased significantly (cluster P FWE < 0.05) in the right orbital gyrus (Figure 2 (c), Table 4 (e)). We found no GMV changes in the stable group (minimum P FWE = 0.848) and no between-group differences (minimum P FWE = 0.663).
In the total of 123 patients, we also found moderate correlations between the PASAT3 test and GM volumes at baseline, in a number of cortical and deep GM areas (Figure 4 , Table 5 ).
Discussion
In general, GM atrophy has been reported to relate more to disability and cognitive impairment 2,3,22 than WM atrophy; 11 however, to some extent the specific lesion location seems to be associated with symptom development in MS, 23 which might partially explain the 'clinico-radiologic paradox' of modest association of clinical and radiological findings. 24 The rate of brain atrophy during the RRMS disease course seems to correlate better with future clinical disability than with disability measures at that timepoint. 25 Moreover, it is yet undetermined if GM atrophy is the result of GM pathology (e.g. CLs) and/or indirectly the result of Wallerian degeneration, due to an increasing WM lesion burden or WM lesions in specific tracts.
In the present study, we didn't find global volume changes over 1 year, neither in the progressive nor in the stable EDSS and MSFC groups, respectively. In contrast, regional GM volume reductions occurred in the right parietal lobe, which is consistent with previous work showing significant loss of apparent cortical grey matter (cGM) thickness over 1 year in parietal and precentral areas, in progressive disability, compared to stable disability. 10 However, in the latter study, MS patients with progressive disability had 29% higher baseline EDSS, 303% higher T2 lesion volumes, and a combined analysis of RRMS 
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Results of a subgroup with optimally pair-wise matched subjects of n = 13 (progressive) vs. n = 13 (stable) is presented in italic letters, below the other results. a No changes in medication during fu. b All patients had been relapse-free and interacted with steroids for at least 1 month, at the time of the BL and fu scan. BL: baseline; EDSS: Expanded Disability Status Scale; fu: follow-up scan (1 year); Gd: gadolinium; GMV: grey matter volume; GMVC: grey matter volume change; IQR: interquartile range; LV: lesion volume; NT: not treated; T: treated. and SPMS patients was performed. Our finding of an effect in the right hemisphere is generally consistent with another study of different MS types, although the patients in that study had larger hyperintense lesion volumes (by 64%) and a shorter mean disease duration of 1.8 years. 13 Interestingly, no signficant GMV changes occured in the motor cortices during follow up in this study. This is strikingly consistent with our own previous results in similar samples of the same dataset. 6, 19 The patients in the present sample might have reached a steady state in GM atrophy in motor cortex, due to their good adherence to an adequate therapy with immunomodulatory drugs, their relatively advanced disease duration and age. Soft factors such as fatigue are also included in the EDSS. Thus, progression in disability measured by EDSS may partly be attributed to fatigue. Previous studies reported cortical atrophy of the parietal lobe relates to fatigue. 26, 27 The authors suggest that dysfunctions in higher-order aspects of the motor control and attention system play a major role in determining fatigue in MS. A further study finds a correlation between fatigue and GM atrophy in the primary sensorimotor area. 28 Interestingly, we found a relationship between EDSS progression and regional GM atrophy in the right postcentral gyrus and right precuneus.
Although a previous study reports GM atrophy to better correlate with MSFC than EDSS, in the present study, we only found between-group differences in disability described by EDSS. 11 Furthermore, the authors found a relatively low concordance between MSFC and EDSS progression (Table 6) . 11 In the present study, PASAT3 at baseline correlated with a pattern of widespread regional GM volumes in fronto-temporo-parietal cortices and deep GM. PASAT tests executive function, working memory, information processing and attention. 29 Previous MS studies report left frontal and temporal atrophy to be related to auditory and verbal memory, right frontal atrophy to impairment in episodic and working memory, left and right temporal atrophy to visual/spatial memory, frontal temporal atrophy to learning consistency, precuneus and superior parietal lobule to performance of simple calculation and arithmetic tasks. 29, 30 Such highly interconnected areas might be prone to being affected by axonal degeneration in the WM. 5 
Methodological issues and limitations
Generally, inter-individual differences in WM lesion patterns can influence GMV reductions. However, it is rather unlikely that the observed effects were related to the different distribution of new lesions in the two groups, because the number of new lesions was very small and not significantly different between groups, and the drugs used in this study are known to prevent equally well the occurrence of new inflammatory lesions. 19 Potential differences in lesions or atrophy of the spinal cord or brain stem, respectively, may have contributed to differences in disability, as well as in cortical GMV between the two groups, as MR data of spinal cords were not available for our study. A previous study shows an association of cervical cord atrophy and physical disability, 31 but cortical GM atrophy and cervical cord atrophy are also reported to be independently associated with long-term disability in MS. 32 Progression of T2 and T1 lesion volume has been related to regional GM atrophy, 6 but seems to be not relevant in the present study, where we found no significant WM lesion volume changes over time. Furthermore, GMV changes may be mimicked by GMV fluctuations: Gliosis or pharmaceutical effects may increase brain volume; underlying co-existing pathological processes independent of MS, or the effects of certain pharmaceuticals, may reduce regional brain volume. There is not yet sufficient evidence, however, regarding the association of medication and regional GMV change. Anti-inflammatory drugs are also suggested to slow brain atrophy during the RRMS disease stage. 33 To reduce such confounding effects, patients of the two groups were matched with respect to having medication, but not with respect to the active ingredient. To rule out potential 'pseudoatrophy' (accelerated brain atrophy and decrease in the number of gadolinium-enhancing lesions due to antiinflammatory effects of medication), 34 here we had set strict exclusion criteria concerning the use and changes of immunomodulatory drugs, as well as of corticosteroids.
In a previous longitudinal VBM study, we provided evidence that pooling of MRI data of our two scanners provides reliable results, because pooling of MRI data of different scanners might introduce a systematic error. This issue is extensively discussed elsewhere. 19 The magnitude of change as shown, for example, in the precuneus of the pair-wise matched groups of patients (cluster size 792 voxels; cluster p corrected < 0.001; change of contrast estimate at voxel 6/-63/53: ≈0.07; n = 19) is rather small. It was, however, consistent with the magnitude of the disease-related effects found in the previous longitudinal VBM study, 19 in a larger sample of the same dataset (precuneus: cluster size 887 voxels; cluster p corrected 0.005; change of contrast estimate at voxel 6/-71/74: ≈0.06; n = 73).
In the present study, age-related structural changes might have interfered with disease-specific effects. Although we included age as a covariate in the statistical model, and saw a relatively small longitudinal age change, we cannot completely exclude a potential confounder of 'aging' in the current study. 35 EDSS is a method summing up several components to quantify disability, with emphasis on the evaluation ambulation and only marginally assessing cognition. A global approach is not the most sensitive tool to look for regional GMV changes, because patients with progressive EDSS may show progression in different functional systems, thus affecting different regions of the cortex. In the For each individual region from left to right: 1. Superimposed image of the significant GMV differences (P < 0.01 corrected) onto an MNI-template. 2. Mean signal intensities ('eigenvalues') for the interaction between the effects of disability (progressive versus stable) and time (baseline versus follow-up scan) in a variety of cortical regions. 3. Contrast estimates and 90% CI for the differential effects. Results shown in Figure 3 present study, several shortcomings of EDSS 14 were considered. Only patients with a baseline EDSS < 5.0 were included, because the clinical importance of a 1.0-point change varies according to the starting score. 14 Sustained improvement in EDSS occurring very frequently in RRMS might contribute to imprecision in disability progression measurement by EDSS. Thus, to control for EDSS fluctuations, we assessed confirmed disability progression, 1 year after the follow-up date. 14 Furthermore, we improved intra-and inter-examiner reliability by using a standardised version of the EDSS.
The lack of association between MSFC progression and GM atrophy found in our data might be due to the relatively small cohort. Furthermore, MSFC still lacks an accepted definition of clinically meaningful change. 36 To enable comparison across studies, in the present study the significant worsening in MSFC was defined as a 25% change in one component that was sustained over 1 year. It is noteworthy that the influence of floor and ceiling effects on MSFC progression was not ruled out. 14 
Conclusion
These results suggested that cortical regional GMV reductions in the right precuneus and in the right postcentral gyrus were associated with disability progression, as measured by EDSS. Future longer-term studies should clarify the association of regional GM atrophy to disability progression in more specific clinical functions, such as motor and cognitive impairment, depression, or fatigue. 
